Answers are grounded in this paper and cite their sources.
Trifluperidol (2a) is a dopamine (D2) receptor antagonist of the butyrophenone type. Carbon/silicon exchange (sila-substitution) in the 4-position of the piperidine ring of 2a (R3COH → R3SiOH) results in sila-trifluperidol (2b). The silanol 2b was synthesized in a multistep synthesis, starting from triethoxy(vinyl)silane, and was isolated as the hydrochloride 2b·HCl. Compound 2b·HCl was structurally characterized by single-crystal X-ray diffraction and solution NMR spectroscopy, and the stability of the silanol 2b in aqueous solutions at different pH values was studied by ESI-MS experiments. In addition, the pharmacological profiles of the C/Si analogues trifluperidol (2a) and sila-trifluperidol (2b) and of the related compounds haloperidol (1a) and sila-haloperidol (1b) were studied in functional receptor assays at human dopamine D1 and D2 receptors. Sila-substitution of 1a (→ 1b) and 2a (→ 2b) affects the pharmacological properties significantly.
No takes yet. Share an insight, caveat, or question.
Tacke et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: